19.19
Precedente Chiudi:
$14.95
Aprire:
$15.5
Volume 24 ore:
1.35M
Relative Volume:
5.04
Capitalizzazione di mercato:
$307.78M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.57%
1M Prestazione:
+12.82%
6M Prestazione:
-16.05%
1 anno Prestazione:
-52.76%
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NGNE
Neurogene Inc
|
19.19 | 307.78M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
2024-06-11 | Iniziato | Robert W. Baird | Outperform |
2024-04-29 | Iniziato | Leerink Partners | Outperform |
2024-03-21 | Iniziato | William Blair | Outperform |
2024-01-08 | Iniziato | H.C. Wainwright | Buy |
2024-01-05 | Iniziato | Stifel | Buy |
2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance
Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World
Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus
Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria
BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World
Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus
Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks
Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada
Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World
Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks
Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
BNP Paribas Financial Markets Cuts Stake in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Reports Q1 2025 Financial Progress and Updates - TipRanks
Northern Trust Corp Buys 5,845 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
BMO Capital Markets Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - Defense World
Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | - GuruFocus
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | NGNE Stock News - GuruFocus
Neurogene stock target raised to $22 by BMO Capital - Investing.com Nigeria
ASGCT Roundup: Sarepta, Rocket, Neurogene and the World’s First Tailored CRISPR Therapy - NewsBreak: Local News & Alerts
Neurogene introduces gene therapy monitoring system after patient death - Yahoo Finance
Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Robert W. Baird - Defense World
Baird R W Downgrades Neurogene (NASDAQ:NGNE) to Hold - Defense World
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy Complication | NGNE Stock News - GuruFocus
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | NGNE Stock News - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 - Investing.com
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):